Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients with inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. Curanex Pharmaceuticals Inc was founded in 1996 and is headquartered in Jericho, New York.…
Curanex Pharmaceuticals (NASDAQ: CURX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 6 employees.
The shares were at 4.410 USD on 20 November 2026, down 50.0% over 52 weeks. Its 52-week range is 3.576 USD to 90.00 USD: the price is 95.1% below the high and 23.3% above the low.
Its market capitalisation is 6.92M USD.
Curanex Pharmaceuticals reports return on equity of -37.7% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 2.66M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.